Compare Stocks → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGLENASDAQ:CALCNASDAQ:IMRXNASDAQ:JAGX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsCALCCalciMedica$5.74-4.3%$4.46$1.75▼$8.59$61.65M1.3721,063 shs6,700 shsIMRXImmuneering$1.64+5.1%$3.19$1.38▼$11.92$48.63M-0.6560,974 shs340,500 shsJAGXJaguar Health$0.32+8.5%$0.12$0.05▼$1.22$87.84M0.8953.87 million shs142.47 million shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%+200.25%CALCCalciMedica0.00%+5.32%+31.95%+12.55%+69.32%IMRXImmuneering0.00%+11.56%-25.11%-70.29%-79.45%JAGXJaguar Health0.00%+76.67%+278.57%+256.90%-50.31%Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACALCCalciMedica3.9364 of 5 stars3.55.00.00.04.43.30.6IMRXImmuneering4.0417 of 5 stars4.33.00.00.01.85.01.3JAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGLEAeglea BioTherapeutics2.50Moderate Buy$17.50∞ UpsideCALCCalciMedica3.00Buy$18.67225.20% UpsideIMRXImmuneering2.50Moderate Buy$13.50723.17% UpsideJAGXJaguar HealthN/AN/AN/AN/ACurrent Analyst RatingsLatest AGLE, CALC, IMRX, and JAGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.004/2/2024IMRXImmuneeringMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $8.004/1/2024CALCCalciMedicaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$14.004/1/2024CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/15/2024IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $16.003/15/2024IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $15.003/15/2024IMRXImmuneeringTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform3/15/2024IMRXImmuneeringJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$16.00 ➝ $3.003/14/2024IMRXImmuneeringGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral3/13/2024CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/5/2024IMRXImmuneeringOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$25.00(Data available from 5/6/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGLEAeglea BioTherapeutics$2.33M0.00N/AN/A($60.61) per share0.00CALCCalciMedicaN/AN/AN/AN/A$1.42 per shareN/AIMRXImmuneering$320K151.96N/AN/A$3.09 per share0.53JAGXJaguar Health$9.76M9.00N/AN/A$0.07 per share4.54Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGLEAeglea BioTherapeutics-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/ACALCCalciMedica-$34.36M-$25.59N/AN/AN/AN/A-234.70%-165.69%5/10/2024 (Estimated)IMRXImmuneering-$53.47M-$1.89N/AN/AN/AN/A-52.49%-47.63%N/AJAGXJaguar Health-$41.30MN/A0.00N/AN/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)Latest AGLE, CALC, IMRX, and JAGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023CALCCalciMedica-$1.00-$0.23+$0.77-$0.23N/AN/A3/1/202412/31/2023IMRXImmuneering-$0.46-$0.52-$0.06-$0.52N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/ACALCCalciMedicaN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGLEAeglea BioTherapeuticsN/A4.594.59CALCCalciMedicaN/A2.882.88IMRXImmuneeringN/A11.3511.35JAGXJaguar Health6.332.001.34OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGLEAeglea BioTherapeuticsN/ACALCCalciMedicaN/AIMRXImmuneering67.65%JAGXJaguar Health12.04%Insider OwnershipCompanyInsider OwnershipAGLEAeglea BioTherapeutics6.60%CALCCalciMedica53.30%IMRXImmuneering25.00%JAGXJaguar Health0.02%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGLEAeglea BioTherapeutics694.05 million3.78 millionOptionableCALCCalciMedica1410.74 million5.02 millionNo DataIMRXImmuneering6829.65 million22.24 millionNot OptionableJAGXJaguar Health49276.22 million276.16 millionNo DataAGLE, CALC, IMRX, and JAGX HeadlinesSourceHeadlineInvesting in Tech Penny Stocks Right Now, 3 Tipspennystocks.com - May 1 at 6:14 AMStockNews.com Initiates Coverage on Jaguar Health (NASDAQ:JAGX)americanbankingnews.com - April 30 at 2:30 AMNapo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)accesswire.com - April 29 at 8:30 AM3 Obstacles Investors Face When Buying Penny Stockspennystocks.com - April 23 at 6:37 AMNapo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Careaccesswire.com - April 22 at 8:45 AMJaguar Health gets grant for treating secretory diarrhea associated with microvillous inclusion diseasepharmaceutical-technology.com - April 18 at 11:23 AMJaguar Health Appoints Biopharmaceutical Industry…pharmiweb.com - April 18 at 11:23 AMJaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Careaccesswire.com - April 18 at 8:30 AMJaguar Health licenses Venture Life's US FDA-approved oral mucositis product, Gelclair for US marketpharmabiz.com - April 18 at 6:22 AMWhy Jaguar Health Stock Is Up Todaymsn.com - April 17 at 2:20 AMGold Moves Higher; Morgan Stanley Earnings Top Viewsmarkets.businessinsider.com - April 17 at 2:20 AMWhy Is Jaguar Health (JAGX) Stock Up 44% Today?investorplace.com - April 16 at 11:34 AMJaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Careaccesswire.com - April 16 at 8:30 AMS&P 500 Down 1%; Delta Air Lines Posts Upbeat Earningsbenzinga.com - April 10 at 3:37 PMJaguar Health shareholders approve reverse stock splitmsn.com - April 10 at 3:37 PMWhat Is Going on With Jaguar Health (JAGX) Stock Today?investorplace.com - April 10 at 10:40 AMJaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholdersfinanznachrichten.de - April 10 at 1:23 AMWhy Jaguar Health Stock Is Soaring After-Hoursmsn.com - April 9 at 8:04 PMJaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholdersaccesswire.com - April 9 at 4:15 PMJaguar Health Granted Extension Until August 13, 2…pharmiweb.com - April 8 at 9:51 AMJaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirementaccesswire.com - April 8 at 8:30 AMJaguar Health Full Year 2023 Earnings: US$1.79 loss per share (vs US$36.18 loss in FY 2022)finance.yahoo.com - April 3 at 9:48 AMJaguar Health, Inc. (NASDAQ:JAGX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 2 at 1:47 PMJaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar Internationalaccesswire.com - April 2 at 8:50 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 months3 Value Stocks Buffett Wishes He Could BuyApril 22, 2024 8:35 AMView 3 Value Stocks Buffett Wishes He Could BuyHere’s Why Institutions Had Been Buying Martin Marietta StockApril 29, 2024 8:45 AMView Here’s Why Institutions Had Been Buying Martin Marietta StockAll Headlines Company DescriptionsAeglea BioTherapeuticsNASDAQ:AGLEAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.CalciMedicaNASDAQ:CALCCalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.ImmuneeringNASDAQ:IMRXImmuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.